{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"GUARD-01","nct_id":"NCT05723991","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=guard-01-nct05723991. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Vidiximab (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every 2 weeks","label":"Vidiximab and Gemcitabine Neoadjuvant therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-28","type":"ESTIMATED"},"conditions":["Radical Cystectomy","Urothelial Carcinoma"],"enrollment":{"count":36,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Disitamab Vedotin and Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2023-02-13","lead_sponsor":"Chunguang yang (101937)","official_title":"Evaluation of an Open, Single Arm, Multicenter Phase II Clinical Study on the Neoadjuvant Treatment of HER2 Expressing Myometrial Invasive Bladder Cancer With Disitamab Vedotin for Injection and Gemcitabine","overall_status":"UNKNOWN","phases":["PHASE4"],"primary_completion_date":{"date":"2024-09-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathologic Complete Response","timeFrame":"three years"}],"references":[],"start_date":{"date":"2022-09-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma","url":"https://clinicaltrials.gov/study/NCT05723991"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/guard-01-nct05723991"}